PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
pembrolizumab Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks (NewA2)
|
pembrolizumab Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
atezolizumab + RG6058 Sensitive: B - Late Trials
Roche Press Release - 2 weeks (NewB)
|
atezolizumab + RG6058 Sensitive: B - Late Trials
Roche Press Release - 2 weeks - (New B)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Lung Cancer - 3 weeks (NewC3)
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Lung Cancer - 3 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
cemiplimab Sensitive: A1 - Approval
|
cemiplimab Sensitive: A1 - Approval
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
PD-L1 overexpression
|
Urothelial Cancer
|
PD-L1 overexpression
|
Urothelial Cancer
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
cemiplimab Sensitive: A2 - Guideline
|
cemiplimab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
|
carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
carboplatin + gemcitabine Sensitive: B - Late Trials
|
carboplatin + gemcitabine Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
|
cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
GC Sensitive: B - Late Trials
|
GC Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
carboplatin + pemetrexed Sensitive: B - Late Trials
|
carboplatin + pemetrexed Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
cisplatin + pemetrexed Sensitive: B - Late Trials
|
cisplatin + pemetrexed Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD1 inhibitor Sensitive: B - Late Trials
|
PD1 inhibitor Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Urothelial Cancer
|
PD-L1 overexpression
|
Urothelial Cancer
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
avelumab Sensitive: B - Late Trials
|
avelumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastric Cancer
|
PD-L1 overexpression
|
Gastric Cancer
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Prostate Cancer
|
PD-L1 overexpression
|
Prostate Cancer
|
atezolizumab + enzalutamide capsule Sensitive: B - Late Trials
|
atezolizumab + enzalutamide capsule Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastric Cancer
|
PD-L1 overexpression
|
Gastric Cancer
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Ovarian Cancer
|
PD-L1 overexpression
|
Ovarian Cancer
|
atezolizumab Sensitive: C1 - Off-label
|
atezolizumab Sensitive: C1 - Off-label
|
PD-L1 overexpression
|
Urothelial Cancer
|
PD-L1 overexpression
|
Urothelial Cancer
|
PF-06801591 Sensitive: C2 – Inclusion Criteria
|
PF-06801591 Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
Sarcoma
|
PD-L1 overexpression
|
Sarcoma
|
nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
|
nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
pembrolizumab + niraparib Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + niraparib Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
retifanlimab Sensitive: C2 – Inclusion Criteria
|
retifanlimab Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
AB122 + AB154 + AB928 Sensitive: C2 – Inclusion Criteria
|
AB122 + AB154 + AB928 Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
Cervical Cancer
|
PD-L1 overexpression
|
Cervical Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
camrelizumab Sensitive: C3 – Early Trials
|
camrelizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Peripheral T-cell Lymphoma
|
PD-L1 overexpression
|
Peripheral T-cell Lymphoma
|
GB226 Sensitive: C3 – Early Trials
|
GB226 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
nivolumab + ibrutinib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Prostate Cancer
|
PD-L1 overexpression
|
Prostate Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Gastric Cancer
|
PD-L1 overexpression
|
Gastric Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NHL
|
PD-L1 overexpression
|
NHL
|
avelumab Sensitive: C3 – Early Trials
|
avelumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Solid Tumor
|
PD-L1 overexpression
|
Solid Tumor
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NHL
|
PD-L1 overexpression
|
NHL
|
AB122 Sensitive: C3 – Early Trials
|
AB122 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
MGD013 Sensitive: C3 – Early Trials
|
MGD013 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Bladder Cancer
|
PD-L1 overexpression
|
Bladder Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
LUAD
|
PD-L1 overexpression
|
LUAD
|
pemetrexed Sensitive: C3 – Early Trials
|
pemetrexed Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Thyroid Gland Carcinoma
|
PD-L1 overexpression
|
Thyroid Gland Carcinoma
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Thyroid Gland Anaplastic Carcinoma
|
PD-L1 overexpression
|
Thyroid Gland Anaplastic Carcinoma
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Solid Tumor
|
PD-L1 overexpression
|
Solid Tumor
|
avelumab + eftilagimod alpha Sensitive: C3 – Early Trials
|
avelumab + eftilagimod alpha Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Solid Tumor
|
PD-L1 overexpression
|
Solid Tumor
|
eftilagimod alpha Sensitive: C3 – Early Trials
|
eftilagimod alpha Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
PF-06801591 Sensitive: C3 – Early Trials
|
PF-06801591 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Melanoma
|
PD-L1 overexpression
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Gastric Cancer
|
PD-L1 overexpression
|
Gastric Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Bladder Cancer
|
PD-L1 overexpression
|
Bladder Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
pembrolizumab + LY3500518 Resistant: C3 – Early Trials
|
pembrolizumab + LY3500518 Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
Melanoma
|
PD-L1 overexpression
|
Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Head and Neck Cancer
|
PD-L1 overexpression
|
Head and Neck Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
M7824 Sensitive: C3 – Early Trials
|
M7824 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Melanoma
|
PD-L1 overexpression
|
Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Melanoma
|
PD-L1 overexpression
|
Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Ovarian Cancer
|
PD-L1 overexpression
|
Ovarian Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
RCC
|
PD-L1 overexpression
|
RCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
olaparib Resistant: C3 – Early Trials
|
olaparib Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
nivolumab + MGCD516 Sensitive: C3 – Early Trials
|
nivolumab + MGCD516 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
LUAD
|
PD-L1 overexpression
|
LUAD
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
ipilimumab + cemiplimab Sensitive: C3 – Early Trials
|
ipilimumab + cemiplimab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
AB122 Sensitive: C3 – Early Trials
|
AB122 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Nasopharyngeal Carcinoma
|
PD-L1 overexpression
|
Nasopharyngeal Carcinoma
|
AB122 Sensitive: C3 – Early Trials
|
AB122 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
|
R-CHOP Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
pembrolizumab + afatinib Sensitive: C3 – Early Trials
|
pembrolizumab + afatinib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
AB122 + AB154 Sensitive: C3 – Early Trials
|
AB122 + AB154 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
PD-L1 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Gastric Cancer
|
PD-L1 overexpression
|
Gastric Cancer
|
SHR-1701 Sensitive: C3 – Early Trials
|
SHR-1701 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
SHR-1701 Sensitive: C3 – Early Trials
|
SHR-1701 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
anlotinib + AK104 Sensitive: C3 – Early Trials
|
anlotinib + AK104 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
durvalumab Sensitive: C3 – Early Trials
|
durvalumab Sensitive: C3 – Early Trials
|